EFM
MRSN

E Fund Management’s Mersana Therapeutics MRSN Stock Holding History

E Fund Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-696
Closed -$78K – 354
2024
Q1 		$78K Buy
+696
New +$69.2K ﹤0.01% 367
2023
Q3 		– Sell
-724
Closed -$60K – 310
2023
Q2 		$60K Sell
724
-379
-34% -$55.4K ﹤0.01% 307
2023
Q1 		$113K Buy
1,103
+229
+26% +$32.1K 0.01% 320
2022
Q4 		$128K Buy
874
+286
+49% +$48.3K 0.01% 320
2022
Q3 		$99K Buy
+588
New +$95.6K 0.01% 327

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management's MRSN Position: Q2 2024 in Review

E Fund Management sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 696 shares — an estimated $78K sold.

E Fund Management first reported a position in MRSN in Q3 2022 and held it in 5 quarters. The position peaked at $128K in Q4 2022. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • E Fund Management reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • E Fund Management sold 696 Mersana Therapeutics shares in Q2 2024, an estimated $78K.
  • E Fund Management first reported a position in Mersana Therapeutics in Q3 2022 and held it in 5 quarters.
  • E Fund Management's Mersana Therapeutics position peaked at $128K in Q4 2022.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on E Fund Management's 13F filing for Q2 2024, filed 12 Aug 2024.